Impact of combined hormonal therapy on coagulation inhibitory proteins

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The objective of this study was to determine the effect of two combined oral contraceptives on two inhibitory coagulation proteins. The study included 56 women between ages 20 and 55, twenty six of them taking 30μg ethinyloestradiol (EE) and 75μg gestodene (GSD) and thirty of them taking 30 μg ethinyloestradiol and 75 μg levonogestrel (LNG) for two months. The subjects were healthy and they had not taken any other drug two months before starting the hormonal therapy. Plasma was used for measuring protein C and antithrombin III (AT III), before using the pill and after stopping it. Comparison of the values of protein C and AT III between two periods (before and after treatment) showed the following results: Concentrations of protein C was significantly increased while AT III level was decreased after treatment with 30 μg EE/ 75 μg GSD (p=0.001). Treatment with 30 μg EE/ 75 μg LNG showed no significant change in the level of AT III (p=0.058) and significantly increased protein C concentration (p=0.001). We conclude that treatment with 30 μg EE/ 75 μg GSD induces more changes in the inhibitory coagulation proteins than treatment with 30 μg EE/ 75 μg LNG, indicating an increased risk for thrombotic diseases.

Cite

CITATION STYLE

APA

Ibrahimi, E., & Koni, M. (2016). Impact of combined hormonal therapy on coagulation inhibitory proteins. Eastern Journal of Medicine, 21(1), 10–13. https://doi.org/10.5505/ejm.2016.52388

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free